Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies

TY - JOUR

T1 - Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes?

T2 - Evidence Based on Experimental and Clinical Studies

AU - Petersen, Karen Ekkelund

AU - Rakipovski, Günaj

AU - Raun, Kirsten

AU - Lykkesfeldt, Jens

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential 'antioxidant' activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.

AB - Glucagon-like peptide-1 (GLP-1) has shown to influence the oxidative stress status in a number of in vitro, in vivo and clinical studies. Well-known effects of GLP-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ROS level, production and antioxidant capacity have been suggested to also play a role. The potential 'antioxidant' activity of GLP-1 along with other proposed glucose-independent modes of action related to ameliorating redox imbalance remains a controversial topic but could hold a therapeutic potential against micro- and macrovascular diabetic complications. This review discusses the presently available knowledge from experimental and clinical studies on the effects of GLP-1 on oxidative stress in diabetes and diabetes-related complications.

KW - Animals

KW - Diabetes Mellitus, Type 2

KW - Drug Evaluation, Preclinical

KW - Evidence-Based Practice

KW - Glucagon-Like Peptide 1

KW - Humans

KW - Oxidative Stress

KW - Peptides

KW - Reactive Oxygen Species

KW - Venoms

KW - Journal Article

KW - Review

U2 - 10.2174/1573399812666150918150608

DO - 10.2174/1573399812666150918150608

M3 - Review

C2 - 26381142

SN - 1573-3998

VL - 12

SP - 331

EP - 358

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

IS - 4

ER -